N6 heterocyclic 8-modified adenosine derivatives
    1.
    发明授权
    N6 heterocyclic 8-modified adenosine derivatives 有权
    N6杂环8修饰腺苷衍生物

    公开(公告)号:US06294522B1

    公开(公告)日:2001-09-25

    申请号:US09454485

    申请日:1999-12-03

    IPC分类号: A61K3170

    CPC分类号: C07H19/16

    摘要: N6 heterocyclic 8 modified adenosine derivatives that are selective, partial or full adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorders, and treating diabetic disorders and obesity in mammals, and especially in humans.

    摘要翻译: 作为选择性,部分或全部腺苷A1受体部分或全部激动剂的N6杂环8修饰的腺苷衍生物,因此可用于改善心脏活动,修饰脂肪细胞功能,治疗中枢神经系统疾病,以及治疗哺乳动物的糖尿病病症和肥胖症 ,特别是在人类。

    Aralkyl substituted piperazine compounds
    4.
    发明授权
    Aralkyl substituted piperazine compounds 失效
    芳烷基取代的哌嗪化合物

    公开(公告)号:US06552023B2

    公开(公告)日:2003-04-22

    申请号:US09791133

    申请日:2001-02-22

    IPC分类号: A61K31495

    摘要: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.

    摘要翻译: 新的通式化合物及其药学上可接受的酸加成盐,其中所述化合物可用于治疗以保护骨骼肌免受创伤损伤或保护肌肉或全身性疾病如间歇性跛行后的骨骼肌,以治疗休克 条件,以维持移植中使用的供体组织和器官,治疗包括心房和室性心律失常的心血管疾病,Prinzmetal(变体)心绞痛,稳定性心绞痛和运动诱发的心绞痛,充血性心脏病和心肌梗死。

    Pyrrolo[2,3-]pyridine kinase inhibitors
    10.
    发明授权
    Pyrrolo[2,3-]pyridine kinase inhibitors 有权
    吡咯并[2,3]吡啶激酶抑制剂

    公开(公告)号:US08901301B2

    公开(公告)日:2014-12-02

    申请号:US12721496

    申请日:2010-03-10

    CPC分类号: C07D471/04 A61K31/437

    摘要: Propane-1-sulfonic acid {2,4-difluoro-3-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide, propane-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, propane-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-amide, N-[3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2,5-difluoro-benzenesulfonamide, N-[3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-3-fluoro-benzenesulfonamide, pyrrolidine-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, N,N-dimethylamino-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, and forms thereof are active on at least one Raf protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Raf protein kinases, including melanoma, glioma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, and biliary tract cancer.

    摘要翻译: 丙烷-1-磺酸{2,4-二氟-3- [5-(2-甲氧基 - 嘧啶-5-基)-1H-吡咯并[2,3-b]吡啶-3-羰基] - 苯基} 酰胺,丙烷-1-磺酸[3-(5-氰基-1H-吡咯并[2,3-b]吡啶-3-羰基)-2,4-二氟 - 苯基] - 酰胺,丙烷-1-磺酸 [3-(5-氰基-1H-吡咯并[2,3-b]吡啶-3-羰基)-2-氟 - 苯基] - 酰胺,N- [3-(5-氰基-1H-吡咯并[ 3-b]吡啶-3-羰基)-2,4-二氟 - 苯基] -2,5-二氟 - 苯磺酰胺,N- [3-(5-氰基-1H-吡咯并[2,3-b] 吡咯-3-羰基)-2,4-二氟 - 苯基] -3-氟 - 苯磺酰胺,吡咯烷-1-磺酸[3-(5-氰基-1H-吡咯并[2,3-b]吡啶-3-羰基) -2,4-二氟 - 苯基] - 酰胺,N,N-二甲基氨基磺酸[3-(5-氰基-1H-吡咯并[2,3-b]吡啶-3-羰基)-2,4-二氟 - 苯基] - 酰胺及其盐,其制剂,其缀合物,其衍生物,其形式及其用途。 在某些方面和实施方案中,所述的化合物或其盐,其制剂,其缀合物,其衍生物及其形式在至少一种Raf蛋白激酶上具有活性。 还描述了其用于治疗疾病和病症的方法,包括与Raf蛋白激酶(包括黑素瘤,神经胶质瘤,结肠直肠癌,甲状腺癌,肺癌,卵巢癌,前列腺癌和胆道癌)的活性相关的疾病和病症。